Blueprint Medicines Corp (BPMC)

65.89
+0.03(+0.05%)
After Hours
65.89
0.00(0.00%)
- Real-time Data
  • Volume:
    390,775
  • Day's Range:
    65.85 - 68.30
  • 52 wk Range:
    43.46 - 117.86

BPMC Overview

Prev. Close
65.86
Day's Range
65.85-68.3
Revenue
221.24M
Open
65.86
52 wk Range
43.46-117.86
EPS
-11.86
Volume
390,775
Market Cap
3.93B
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
806,444
P/E Ratio
-5.45
Beta
0.935
1-Year Change
-35.22%
Shares Outstanding
59,719,570
Next Earnings Date
Oct 27, 2022
What is your sentiment on Blueprint Medicines Corp?
or
Market is currently closed. Voting is open during market hours.

Blueprint Medicines Corp News

Welcome to Your News Upgrade

Be the First to Know and Act on Market Moving News.

Welcome to Your News Upgrade

Blueprint Medicines Corp Analysis

Blueprint Medicines Corp Company Profile

Blueprint Medicines Corp Company Profile

Employees
495

Blueprint Medicines Corporation is a global precision therapy company that is inventing medicines for people with cancer and blood disorders. The Company delivers its approved medicines, including AYVAKIT/AYVAKYT (avapritinib) and GAVRETO (pralsetinib) to patients in the United States and Europe, and it is globally advancing multiple programs for systemic mastocytosis (SM), lung cancer and other genomically defined cancers, and cancer immunotherapy. Its pipelines also include BLU-263 (KIT), AYVAKIT (avapritinib) (PDGFRA), BLU-701 (EGFR), BLU-945 (EGFR), BLU-451 (EGFR exon 20 insertions), BLU-222 (CDK2) and BLU-852 (MAP4K1). It is developing and commercializing avapritinib for the treatment of advanced SM, and developing avapritinib for the treatment of non-advanced SM. The Company is developing BLU-263, an investigational, orally available KIT inhibitor, for the treatment of non-advanced SM and other mast cell disorders.

Read More

Analyst Price Target

Average91.00 (+38.11% Upside)
High152
Low40
Price65.89
No. of Analysts15
Strong Sell
Sell
Neutral
Buy
Strong Buy
Buy
Analysts 12-Month Price Target

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellStrong SellStrong SellSellBuy
Technical IndicatorsStrong SellStrong SellSellStrong SellStrong Sell
SummaryStrong SellStrong SellStrong SellStrong SellNeutral
  • There we go. Not big profit but a profit in a red day for the industry.
    0
    • Anyone loading for tomorrow? I am.
      0
      • bought on the dip, fda going to spike the price
        0
        • where is the spike ?
          0
      • https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(21)00247-3/fulltext
        0
        • PDUFA date coming up
          0
          • the average target price is 93.5 and the high target price is 122 why is nobody buying?
            0